

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-11 (canceled)

Claim 12 (currently amended): A method for treating ~~or preventing a disorder associated with hypocoagulation~~ ~~hemophilia or von Willebrand's disease~~ in a subject, said method comprising administering to said subject an inducer of P-selectin activity selected from the group consisting of a soluble P-selectin polypeptide and a P-selectin fusion protein, such that the ~~hemophilia or von Willebrand's disease disorder associated with hypocoagulation~~ is treated or prevented.

Claim 13 (currently amended): The method of claim 12, wherein said ~~disorder~~ ~~hemophilia is a hemorrhagic disorder~~ hemophilia A.

Claim 14 (currently amended): The method of claim 12, wherein said ~~disorder~~ ~~hemophilia is~~ hemophilia B.

Claim 15 (original): The method of claim 12, wherein the inducer of P-selectin activity increases the level of soluble P-selectin polypeptide in the plasma of the subject.

Claims 16-18 (canceled)

Claim 19 (withdrawn): The method of claim 18, wherein said subject is further treated with a molecule effective to induce a procoagulant state in tumor associated vasculature.

Claim 20 (withdrawn): The method of claim 19, wherein said molecule comprises a first binding region that binds to a component of a tumor cell or tumor associated vasculature, operatively linked to a coagulation factor or a second binding region that binds to a coagulation factor.

Claim 21 (withdrawn): The method of claim 20, wherein said first binding region comprises an antibody, or an antigen binding fragment thereof, that binds to VCAM-1, operatively linked to tissue factor.

Claim 22-50 (canceled)

Claim 51 (currently amended): The method of claim 12 claims 12 or 14, wherein the inducer of P-selectin activity is a fusion protein.

Claim 52 (currently amended): The method of claim 12 claims 12 or 14, wherein the P-selectin fusion protein comprises a soluble P-selectin polypeptide operatively linked to an immunoglobulin.

Claim 53 (currently amended): The method of claim 52, wherein the immunoglobulin is a human IgG1, and the Fc region of the immunoglobulin is fused to the C-terminus of at least one soluble P-selectin polypeptide sequencee.

Claim 54 (withdrawn): A pharmaceutical composition for administration to a subject *in vivo*, said pharmaceutical composition comprising a fusion protein.

Claim 55 (withdrawn): The pharmaceutical composition of claim 53 wherein the fusion protein comprises a soluble P-selectin polypeptide operatively linked to an immunoglobulin.

Claim 56 (withdrawn): The pharmaceutical composition of claim 54 wherein the immunoglobulin is a human IgG1, and the Fc region of the immunoglobulin is fused to the C-terminus of at least one soluble P-selectin polypeptide.

Claim 57 (withdrawn): A pharmaceutical composition for administration to a subject *in vivo*, said pharmaceutical composition comprising a small molecule.